Marília Silveira de Almeida Campos

Marília Silveira de Almeida Campos

Auto-generated profile, based on publicly available information

Marília Silveira de Almeida Campos

Universidade de São Paulo, Brasil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2016 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
MCMarília Silveira De Almeida Campos
Marília Silveira De Almeida Campos
LALorena Rocha Ayres
Lorena Rocha Ayres
MMManuela Roque Siane Morelo
Manuela Roque Siane Morelo
FMFabiana Angelo Marques
Fabiana Angelo Marques
LPLeonardo Pereira
Leonardo Pereira

9 May 2018 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
MCMarília Silveira de Almeida Campos
Marília Silveira de Almeida Campos
LALorena Rocha Ayres
Lorena Rocha Ayres
MMManuela Roque Siane Morelo
Manuela Roque Siane Morelo
FCFabiana Angelo Marques Carizio
Fabiana Angelo Marques Carizio
LPLeonardo Pereira
Leonardo Pereira

31 January 2015 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LALorena Rocha Ayres
Lorena Rocha Ayres
MCMarília Silveira de Almeida Campos
Marília Silveira de Almeida Campos
TGThais de Oliveira Gozzo
Thais de Oliveira Gozzo
Edson Zangiacomi MartinezEdson Zangiacomi Martinez
Edson Zangiacomi Martinez
AUAndrea Queiróz Ungari
Andrea Queiróz Ungari
LPLeonardo Pereira
Leonardo Pereira

18 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJoão Paulo Vilela Rodrigues
João Paulo Vilela Rodrigues
FMFabiana Angelo Marques
Fabiana Angelo Marques
AGAna Maria Rosa Freato Gonçalves
Ana Maria Rosa Freato Gonçalves
MCMarília Silveira de Almeida Campos
Marília Silveira de Almeida Campos
TRTiago Marques Reis
Tiago Marques Reis
LPLeonardo Pereira
Leonardo Pereira
It is estimated that around five to 10.0% of hospital admissions occur due to clinical conditions resulting from pharmacotherapy. Clinical pharmacist's activity can enhance drug therapy's effectiveness and safety through pharmacotherapy interventions (PIs), thus minimizing drug-related problems (DRPs) and optimizing the allocation of financial resources associated with health care. This study aimed to estimate the DRPs prevalence, evaluate PI which were performed by clinical pharmacists in the Neurology Unit of a Brazilian tertiary teaching hospital and to identify factors associated with the occurrence of PI-related DRP. A single-arm trial included adults admitted in the referred Unit from 2012 July to 2015 June. Patients were evaluated during their hospitalization period and PIs were performed based on trigger DRPs that were detected in medication reconciliation (admission or discharge) or during inpatient follow-up. Student's t-test, Chi-square test, Pearson and Multiple logistic regression models to analise the association among age, number of drugs, hospitalization period, and number of diagnoses with occurrence of DRPs. Analyses level of significance was 5%. In total 409 inpatients were followed up [51.1% male, mean age of 49.1 (SD 16.5)]. Patients received, on average, 11.9 (SD 5.8) drugs, ranging from two to 38 drugs per patient, and 54.3% of the sample presented at least one DRP whose most frequent description was "untreated condition". From all 516 performed PIs that resulted from DRPs, 82.8% were accepted and the majority referred to "drug introduction" (27.5%). Multiple logistic regression showed that age, length of hospital stay, number of drugs used, diagnosis of epilepsy, multiple sclerosis and myasthenia gravis would be clinical variables associated with DRP (p < 0,05). Monitoring the use of drugs allowed the clinical pharmacist to detect DRPs and to suggest interventions that promote rational pharmacotherapy.

21 February 2013 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
ABAnna Paula de Sá Borges
Anna Paula de Sá Borges
MCMarília Silveira de Almeida Campos
Marília Silveira de Almeida Campos
LPLeonardo Pereira
Leonardo Pereira

1 January 2021 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
LPLucas Borges Pereira
Lucas Borges Pereira
MZMaria Olívia Barboza Zanetti
Maria Olívia Barboza Zanetti
LSLarissa Pombeiro Sponchiado
Larissa Pombeiro Sponchiado
JRJoão Paulo Vilela Rodrigues
João Paulo Vilela Rodrigues
MCMarília Silveira de Almeida Campos
Marília Silveira de Almeida Campos
LPLeonardo Pereira
Leonardo Pereira
This systematic review aimed to assess antibiotic use in Brazilian hospitals in the 21st century, as well as to understand the different drug utilization metrics adopted to assess the consumption of these drugs. We systematically reviewed five databases (MEDLINE [Medical Literature Analysis and Retrieval System Online], CENTRAL [The Cochrane Central Register of Controlled Trials], EMBASE® [Excerpta Medica Database], Scopus [Elsevier's abstract and citation database], and LILACS [Literatura Latino-Americana e do Caribe em Ciências da Saúde]) for observational or experimental studies that assessed antibiotic utilization in Brazilian hospitals. The main outcomes were the drug utilization metrics and the consumption of antibiotics. We included 23 studies, of which 43.5% were carried out in adult and pediatric care units, 39.1% in adult units, and 17.4% in pediatric units. Regarding the complexity of healthcare, 26.1% of the studies were performed in intensive care units. Two drug utilization metrics were used in these studies: the defined daily dose (DDD) and the percentage of antibiotic prescriptions. The most commonly used antibiotic classes were third-generation cephalosporins, carbapenems, fluoroquinolones, and combinations of penicillins when the DDD was the adopted drug utilization metric. Although few studies have been conducted, existing data indicate a high use of broad-spectrum antibiotics. We found that the lack of standardized antibiotic utilization metrics impaired the mapping of drug consumption at the national level.